Q32 Bio (QTTB) Stock Price, News & Analysis

Company Overview

Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.

Key Stats

• Today's Range: $26.00 to $30.10
• 50-Day Range: $27.28 to $50.59
• 52-Week Range: $9.18 to $53.79
• Volume: 142,830 shs
• Average Volume: 98,487 shs
• Market Capitalization: $332.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $72.33
• Consensus Rating: Buy

Q32 Bio Stock Analysis - MarketRank™

Q32 Bio scored higher than 32% of companies evaluated by MarketBeat, and ranked 816th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Q32 Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Q32 Bio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Q32 Bio are expected to grow in the coming year, from ($12.20) to ($5.71) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Q32 Bio is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Q32 Bio is -1.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Q32 Bio has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.96% of the float of Q32 Bio has been sold short.

Short Interest Ratio / Days to Cover

Q32 Bio has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Q32 Bio has recently increased by 1.11%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Q32 Bio does not currently pay a dividend.

Dividend Growth

Q32 Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.96% of the float of Q32 Bio has been sold short.

Short Interest Ratio / Days to Cover

Q32 Bio has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Q32 Bio has recently increased by 1.11%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for QTTB on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Q32 Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.32% of the stock of Q32 Bio is held by institutions.

QTTB Stock Analysis - Frequently Asked Questions

How have QTTB shares performed this year?

Q32 Bio's stock was trading at $17.04 on January 1st, 2024. Since then, QTTB stock has increased by 60.1% and is now trading at $27.28.
View the best growth stocks for 2024 here.

Who are Q32 Bio's major shareholders?

Top institutional investors of Q32 Bio include FMR LLC (3.50%), Eventide Asset Management LLC (1.56%), Geode Capital Management LLC (1.08%) and State Street Corp (0.90%).
View institutional ownership trends.

How do I buy shares of Q32 Bio?

Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Q32 Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Q32 Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QTTB
• Previous Symbol: NASDAQ:QTTB
• CUSIP: N/A
• CIK: 1661998
• Web: www.homologymedicines.com
• Phone: 781-301-7277
• Fax: N/A
• Employees: 39
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $72.33
• High Stock Price Target: $100.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +165.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($14.2460)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-112,960,000.00
• Net Margins: N/A
• Pretax Margin: -22,326.84%
• Return on Equity: -146.18%
• Return on Assets: -54.49%

Debt

• Debt-to-Equity Ratio: 0.61
• Current Ratio: 6.53
• Quick Ratio: 6.53

Sales & Book Value

• Annual Sales: $1.16 million
• Price / Sales: 286.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.50 per share
• Price / Book: 18.19

Miscellaneous

• Outstanding Shares: 12,180,000
• Free Float: 10,220,000
• Market Cap: $332.27 million
• Optionable: N/A
• Beta: -0.32